a year ago
SRPT
AnalystsGil BlumGil Blum's Stock Forecasts
AnalystsGil Blum
Sectors:
Industries:
Analyst Ranking
Top 3%
#137 out of 5184 analysts
Average Return
+13.43%
Win Rate
39%178 out of 454
Risk vs Reward
Poor
Good
Gil Blum's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Celcuity IncCELC | +1,135.21% | $9.23 | $114.01 | 2025-04-10 - 2026-01-26 | Buy |
Celcuity IncCELC | +1,127.23% | $9.29 | $114.01 | 2025-03-31 - 2026-01-26 | Buy |
Celcuity IncCELC | +983.75% | $10.52 | $114.01 | 2025-05-14 - 2026-01-26 | Buy |
Celcuity IncCELC | +805.56% | $12.59 | $114.01 | 2025-02-05 - 2026-01-26 | Buy |
Celcuity IncCELC | +754.01% | $13.35 | $114.01 | 2025-06-29 - 2026-01-26 | Buy |
Gil Blum Analyst Color
Get additional color on Gil Blum's coverage of popular stocks
2 years ago
AUTL
2 years ago
AUTL
Gil Blum's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Solid Biosciences IncSLDB | 2 | Buy | $16.00 | +148.06% | Reiterates | 13 days ago |
Mereo Biopharma Group PLCMREO | 21 | Buy | $3.00 | +509.76% | Maintains | 15 days ago |
Autolus Therapeutics PLCAUTL | 34 | Buy | $10.00 | +619.42% | Maintains | 15 days ago |
Cartesian Therapeutics IncRNAC | 24 | Buy | $42.00 | +451.91% | Maintains | 18 days ago |
Crispr Therapeutics AgCRSP | 27 | Buy | $80.00 | +46.39% | Reiterates | a month ago |
Absci CorpABSI | 7 | Buy | $7.00 | +142.21% | Reiterates | 2 months ago |
Nurix Therapeutics IncNRIX | 28 | Buy | $26.00 | +38.67% | Reiterates | 2 months ago |
Arcellx IncACLX | 23 | Buy | $105.00 | +53.17% | Reiterates | 2 months ago |
Geron CorpGERN | 23 | Buy | $4.00 | +191.97% | Maintains | 3 months ago |
Tscan Therapeutics IncTCRX | 8 | Buy | $6.00 | +430.97% | Maintains | 3 months ago |
Celcuity IncCELC | 21 | Buy | $70.00 | -38.60% | Reiterates | 3 months ago |
Taysha Gene Therapies IncTSHA | 31 | Buy | $10.00 | +111.86% | Reiterates | 3 months ago |
Artiva Biotherapeutics IncARTV | 7 | Buy | $18.00 | +284.62% | Reiterates | 3 months ago |
Amicus Therapeutics IncFOLD | 2 | Buy | $14.00 | -2.03% | Upgrades | 4 months ago |
Recursion Pharmaceuticals IncRXRX | 25 | Buy | $8.00 | +74.29% | Reiterates | 5 months ago |
Novabridge BiosciencesNBP | 17 | Buy | $6.00 | +48.88% | Reiterates | 5 months ago |
Generation Bio CoGBIO | 18 | Buy | $15.00 | +164.08% | Reiterates | 5 months ago |
Nkarta IncNKTX | 17 | Buy | $10.00 | +306.50% | Reiterates | 5 months ago |
Sarepta Therapeutics IncSRPT | 33 | Hold | $50.00 | +119.30% | Downgrades | 6 months ago |
Rocket Pharmaceuticals IncRCKT | 21 | Hold | $42.00 | +1,057.02% | Downgrades | 8 months ago |
Immunocore Holdings PLCIMCR | 14 | Buy | $71.00 | +102.51% | Reiterates | 10 months ago |
Shattuck Labs IncSTTK | 13 | Hold | $8.00 | N/A | Downgrades | a year ago |
Nextcure IncNXTC | 9 | Buy | $48.00 | N/A | Reiterates | a year ago |
G1 Therapeutics IncGTHX | 17 | Buy | $6.00 | N/A | Maintains | 2 years ago |
Gamida Cell LtdGMDAQ | 8 | Buy | $6.00 | N/A | Reiterates | 2 years ago |
Cti Biopharma CorpCTIC | 5 | Buy | $9.00 | N/A | Reiterates | 3 years ago |
Tectonic Therapeutic IncTECX | 4 | Buy | $72.00 | N/A | Reiterates | 3 years ago |
Fate Therapeutics IncFATE | 1 | Hold | N/A | N/A | Initiates Coverage On | 3 years ago |
Spyre Therapeutics IncSYRE | 1 | Buy | $225.00 | N/A | Maintains | 4 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.